Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016-05-10

Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer.

Related Questions

How do you monitor ovarian function in high risk, premenopausal breast cancer patients receiving adjuvant ovarian suppression?

What is the ideal timing for monitoring and what laboratory tests should be used?

New answer by Medical Oncologist at MOSC Medical College Kolenchery (November 6, 2018)

Great question. Extremely clinically relevant. Here's the problem with 'medical oophorectomy': ABCSG-12 showed that OFS+AI in premenopausal women who were overweight had a 50%...

Read more (2 Answers available)

How would you approach a postmenopausal female with localized ER+ breast cancer on adjuvant anastrozole with a rising estradiol level?

Pre-treatment estradiol: <5 Estradiol after 1 yr: 35

New answer by Medical Oncologist at Lehigh Valley Physicians Group (February 22, 2020)

If the patient was premenopausal at the time of diagnosis but became amenorrheic after chemo, I assume they are still premenopausal and do baseline estradiol and start on tamo...

Read more (3 Answers available)

What is the goal of estradiol levels on ovarian suppression and AI for breast cancer?

Would you recommend aiming for the postmenopausal range as per the lab reference range or do you have a specific goal?

New comment by Medical Oncologist at Joliet Oncology Hematology Associates ( April 8, 2024)

This is very helpful, thank you.

Read more (1 Answer available)